Nimbus licenses IRAK4 inhibitor program to Genentech
Executive Summary
Nimbus Therapeutics licensed Genentech Inc. exclusive global rights to its preclinical interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor program for autoimmune diseases, inflammation, and hematological tumors.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice